Article
Persistent mutation burden drives sustained anti-tumor immune responses.
Nature medicine - 1 Feb 2023
Niknafs Noushin, Balan Archana, Cherry Christopher, Hummelink Karlijn, Monkhorst Kim, Shao Xiaoshan M, Belcaid Zineb, Marrone Kristen A, Murray Joseph, Smith Kellie N, Levy Benjamin, Feliciano Josephine, Hann Christine L, Lam Vincent, Pardoll Drew M, Karchin Rachel, Seiwert Tanguy Y, Brahmer Julie R, Forde Patrick M, Velculescu Victor E, Anagnostou Valsamo
Abstract excerpt
Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical utility in predicting responses in the context of immunotherapy. We evaluated mutations in regions of the genome that are unlikely to undergo loss in a pan-cancer analysis across 31 tumor types (n = 9,242) and eight immunotherapy-treated cohorts of patients with non-small-cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.